Lomitapide

Amryt Announces New Patent for Mycapssa®

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Acromegaly, Birth, Lipodystrophy, Environment, Metreleptin, Degenerative disease, Lomitapide, EMA, Patient, GL, Octreotide, European, Diet, CHMP, Patent, Orange Book, Investment, FDA, Pharmaceutical industry, Dietary supplement, EU

The USPTO has issued to Amryt US Patent No.

Key Points: 
  • The USPTO has issued to Amryt US Patent No.
  • With the addition of this patent, Amryt has ten Orange Book-listed patents for Mycapssa with patent protection through December 2040.
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.
  • Mycapssa has also been submitted to the EMA and has received a positive opinion by the CHMP recommending the approval of Mycapssa in theEuropean Union(EU).

Amryt Supports Acromegaly Awareness Day 2022

Retrieved on: 
Monday, October 31, 2022
Cartilage, Metreleptin, Lipodystrophy, Birth, Diet, AIM, CEO, Forward-looking statement, Heart, Patient, Mortality, GL, Investment, Acromegaly, Awareness, Lomitapide, Degenerative disease, Growth hormone, Hope, COVID-19, Environment, Pharmaceutical industry, Dietary supplement, EU

DUBLIN, Ireland, and Boston MA, October 31, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Acromegaly Awareness Day 2022 which is taking place on November 1, 2022.

Key Points: 
  • DUBLIN, Ireland, and Boston MA, October 31, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Acromegaly Awareness Day 2022 which is taking place on November 1, 2022.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: Acromegaly is a rare endocrine disorder caused by an abundance of growth hormone that signals bones, cartilage, and soft tissues to expand.
  • At Amryt, our mission is to transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need.
  • We are proud to support the global acromegaly community on Acromegaly Awareness Day 2022.

Amryt Supports Global EB Awareness Week 2022

Retrieved on: 
Monday, October 24, 2022
Lists of diseases, Caregiver, Disease, Hope, EMA, Sibling, Lipodystrophy, Acromegaly, Metreleptin, Parent, Patient, List of minor secular observances, AIM, Investment, Awareness, Degenerative disease, Lomitapide, Birth, EB, CEO, Environment, European, Diet, GL, Forward-looking statement, FDA, CHMP, COVID-19, Octreotide, Pharmaceutical industry, Dietary supplement, EU

DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Global Epidermolysis Bullosa (EB) Awareness Week which is taking place October 25 - 31, 2022.

Key Points: 
  • DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Global Epidermolysis Bullosa (EB) Awareness Week which is taking place October 25 - 31, 2022.
  • Amryt is committed to transforming the lives of people affected by rare, debilitating conditions like EB by bringing new treatment options to those in need.
  • EB Awareness Week represents an important opportunity to raise visibility of this devastating condition and the need for expanded treatment options.
  • EB Awareness weekis an important time to increase awareness of the disease, the need for direct support and for commercially available treatments.

Amryt to Report Q3 2022 Results on November 3, 2022

Retrieved on: 
Wednesday, October 19, 2022
Lists of diseases, EMA, Acromegaly, Lipodystrophy, Metreleptin, Patient, Investment, Lomitapide, Birth, Environment, European, Forward-looking statement, Diet, GL, FDA, CHMP, COVID-19, Octreotide, Dietary supplement, Pharmaceutical industry, EU

Access details for the playback facility are as follows: Dial +39 02 802 0987, then press 700723# and 723#.

Key Points: 
  • Access details for the playback facility are as follows: Dial +39 02 802 0987, then press 700723# and 723#.
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly

Retrieved on: 
Tuesday, October 18, 2022
Lists of diseases, Review, EMA, Acromegaly, Lipodystrophy, Metreleptin, Patient, European Directive on Traditional Herbal Medicinal Products, Investment, Degenerative disease, Committee for Medicinal Products for Human Use, Lomitapide, Birth, Committee, CEO, European Medicines Agency, Safety, Maintenance, Environment, Diet, GL, European, Forward-looking statement, FDA, CHMP, COVID-19, COMP, Octreotide, Pharmaceutical industry, Dietary supplement, EU

Mycapssa is already approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

Key Points: 
  • Mycapssa is already approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.
  • The COMP positive opinion is supported by efficacy and safety data from three Phase 3 studies in acromegaly patients including the pivotal MPOWERED Phase 3 trial.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe.
  • Mycapssa has also been submitted to the EMA and has received a positive opinion by the CHMP recommending the approval of Mycapssa in theEuropean Union(EU).

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

Retrieved on: 
Monday, October 17, 2022
Lists of diseases, European Medicines Agency, Loss, Review, EMA, Acquired generalized lipodystrophy, Acromegaly, Lipodystrophy, Insulin resistance, Metreleptin, Patient, Hypertriglyceridemia, Investment, Degenerative disease, Lomitapide, Disorder, Birth, Diabetes, Environment, European, Diet, GL, Forward-looking statement, Fatty liver disease, Adipose tissue, FDA, CHMP, COVID-19, Octreotide, Pharmaceutical industry, Dietary supplement, Health, EU

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.

Key Points: 
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE) technology platform.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Amryt Supports FH Awareness Day – September 24, 2022

Retrieved on: 
Friday, September 23, 2022
People, AIM, Octreotide, COVID-19, Awareness, Diet, Risk, FDA, European, Lists of diseases, Metreleptin, FH, Lipodystrophy, Degenerative disease, Review, Hypercholesterolemia, Stroke, Environment, Forward-looking statement, Patient, Investment, CEO, Lomitapide, Infarction, Diagnosis, Cardiovascular disease, CHMP, Birth, Apolipoprotein, GL, Cholesterol, Acromegaly, Supportive psychotherapy, EMA, Death, Pharmaceutical industry, Dietary supplement, EU

Amryt Supports FH Awareness Day September 24, 2022

Key Points: 
  • Amryt Supports FH Awareness Day September 24, 2022
    DUBLIN, Ireland, and Boston MA, September 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support today for FH Awareness Day 2022 which will take place on Saturday, September 24, 2021.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: All of the Amryt team are pleased to support the great work of the Family Heart Foundation and FH Europe as they seek to raise awareness of this rare and devastating disease.
  • Those with HoFH often go undiagnosed for years and raising awareness is critical to accurate and timely diagnosis that improves outcomes for patients.
  • For our part at Amryt, we are collaborating with all stakeholders to continue to deliver therapies to patients in desperate need.

Amryt Announces New Patent for Mycapssa®

Retrieved on: 
Tuesday, September 13, 2022
Octreotide, COVID-19, Diet, FDA, Lists of diseases, Metreleptin, Lipodystrophy, Degenerative disease, Environment, Forward-looking statement, Patient, Investment, JEB, USPTO, Lomitapide, Orange Book, DEB, Birth, GL, Acromegaly, Patent, EMA, Pharmaceutical industry, Dietary supplement, EU

DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa (octreotide).

Key Points: 
  • DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa (octreotide).
  • The USPTO has issued to Amryt US Patent No.
  • Amryt has nine Orange Book-listed patents for Mycapssa with patent protection through December 2040.
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain

Retrieved on: 
Thursday, September 8, 2022
Acromegaly, COVID-19, EMA, GB, Scar, Birth, CEO, Degenerative disease, Lomitapide, DEB, GL, Lists of diseases, JEB, MAA, Skin, Royal commission, EB, Forward-looking statement, Diet, Octreotide, Medicines and Healthcare products Regulatory Agency, Infection, Investment, Metreleptin, ODD, Ulcer, Lipodystrophy, Patient, FDA, Company, MHRA, Stenosis, Risk, European Commission, Environment, Death, Pharmaceutical industry, Dietary supplement, EU

Joe Wiley, CEO of Amryt Pharma, commented: The approval of Filsuvez by the MHRA is an important development for patients suffering from this debilitating condition and follows the approval of Filsuvez by the European Commission in June.

Key Points: 
  • Joe Wiley, CEO of Amryt Pharma, commented: The approval of Filsuvez by the MHRA is an important development for patients suffering from this debilitating condition and follows the approval of Filsuvez by the European Commission in June.
  • The global market opportunity for EB is estimated by the Company to be in excess of$1.0 billion.
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.
  • Filsuvez is approved in theEU and Great Britain for the treatment of partial thickness wounds associated with JEB and DEB in patients 6 months and older.

Amryt to Report Q2 2022 Results on August 4, 2022

Retrieved on: 
Thursday, July 21, 2022
BST, Investment, Environment, Birth, Acromegaly, DEB, Forward-looking statement, JEB, GL, EMA, Diet, Metreleptin, COVID-19, Lomitapide, Lipodystrophy, FDA, Patient, Octreotide, Lists of diseases, Dietary supplement, Pharmaceutical industry, EU

A playback facility will be available from Aug 4, 2022 at 1230 ET/1730 BST Aug 11, 2022 at 1900 ET/2400 BST.

Key Points: 
  • A playback facility will be available from Aug 4, 2022 at 1230 ET/1730 BST Aug 11, 2022 at 1900 ET/2400 BST.
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE) technology platform.